BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/11/2024 5:28:09 AM | Browse: 78 | Download: 109
 |
Received |
|
2023-11-20 04:12 |
|
Peer-Review Started |
|
2023-11-20 04:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-05 01:44 |
|
Revised |
|
2023-12-13 16:07 |
|
Second Decision |
|
2023-12-27 02:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-12-27 06:59 |
|
Articles in Press |
|
2023-12-27 06:59 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-03 02:53 |
|
Publish the Manuscript Online |
|
2024-01-11 05:28 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Sha-Sha Sun, Xiao-Di Guo, Wen-Dong Li and Jing-Long Chen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Capital Health Development and Scientific Research Special Project |
2022-2-2175 |
|
| Corresponding Author |
Jing-Long Chen, MS, Associate Professor, Department of Oncology, Capital Medical University Affiliated Beijing Ditan Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. hhh540027@126.com |
| Key Words |
Lenvatinib; Sintilimab; Advanced hepatocellular carcinoma; Combination therapy; Tumor response |
| Core Tip |
Currently, advanced hepatocellular carcinoma (HCC)has entered the era of combination therapy. Combination therapy has shown better trend in tumor response and survival outcomes and most combination therapy were dual therapies. The research of triple therapy as first-line treatment for advanced HCC is limited. The purpose of this study was to evaluate the safety and clinical efficacy of triple therapy (lenvatinib + sintilimab + transarterial chemoembolization) in HCC patients with Barcelona Clinic Liver Cancer stage C. We found triple therapy achieved a promising outcome in advanced HCC patients and had manageable effects. |
| Publish Date |
2024-01-11 05:28 |
| Citation |
Sun SS, Guo XD, Li WD, Chen JL. Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma. World J Clin Cases 2023; 12(2): 285-292 |
| URL |
https://www.wjgnet.com/2307-8960/full/v12/i2/285.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v12.i2.285 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
